Imperial College London
Portrait Picture

DrJamesAlexander

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Honorary Senior Lecturer
 
 
 
//

Contact

 

j.alexander

 
 
//

Location

 

Queen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@techreport{Mullish:2022:10.25561/99831,
author = {Mullish, BH},
doi = {10.25561/99831},
title = {National clinical expert consensus statement:  Coronavirus monoclonal antibodies as a prophylactic therapy against COVID-19 for immunocompromised groups},
url = {http://dx.doi.org/10.25561/99831},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - RPRT
AB  - - Novel long-acting coronavirus prophylactic monoclonal antibodytherapies have been shown to be effective in preventing COVID19 in immunocompromised individuals who are at increased riskfrom SARS-CoV-2.- Prophylactic antibody therapies should be made available in atimely manner to give an antibody immunity boost to vulnerablepatients.- Real world evaluations should be co-implemented to provideconfidence of ongoing effectiveness.- Successful delivery of a coronavirus prophylactic antibodytherapy programme would deliver significant benefits tohealthcare systems, communities and immunocompromisedindividuals.
AU  - Mullish,BH
DO  - 10.25561/99831
PY  - 2022///
TI  - National clinical expert consensus statement:  Coronavirus monoclonal antibodies as a prophylactic therapy against COVID-19 for immunocompromised groups
UR  - http://dx.doi.org/10.25561/99831
UR  - https://appg-vulnerablegroups.org/fileadmin/user_upload/Prophylactic_clinical_consensus_statement.pdf
UR  - http://hdl.handle.net/10044/1/99831
ER  -
Download